Agilent Technologies, Inc.(A)Earnings, Financials & Key RatiosAgilent Technologies, Inc. (A) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q2
the company's ability to achieve a 20.2% FCF margin in 2026Q2 while scaling top-line growth to 10.0% suggests a strong operational recovery that justifies its current valuation.
Agilent Technologies, Inc. (A) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Agilent Technologies, Inc. (A) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 27, 2026 | $1.49vs $1.41+5.7% | $1.8Bvs $1.8B+2.0% |
| Q1 2026 | Feb 25, 2026 | $1.36vs $1.37-0.7% | $1.8Bvs $1.8B-0.5% |
| Q4 2025 | Nov 24, 2025 | $1.59vs $1.58+0.4% | $1.8Bvs $1.8B+0.4% |
| Q3 2025 | Aug 27, 2025 | $1.37vs $1.37+0.0% | $1.7Bvs $1.7B+3.2% |
Recent stock market news and headlines for Agilent Technologies, Inc. (A)
[url="]Alpha and Omega Semiconductor Limited[/url] (AOS) (Nasdaq: AOSL), a designer, developer, and global supplier of a broad range of discrete power devices,
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent xCELLigence RTCA eSight AI, a new AI-powered software module that simplifies label-free imaging analysis by reducing manual cell segmentation steps and parameter tuning and supporting more consistent results. The software upgrade enhances the unique dual-readout capabilities of the Agilent xCELLigence RTCA eSight instrument with AI-driven cell imaging analysis, enabling researchers to.
Agilent (A) reported earnings 30 days ago. What's next for the stock?
Denver, CO and London, UK – 25 June 2026: Excellere Partners (“Excellere”), a Denver-based private equity firm specializing in partnering with entrepreneurs and management teams, and GHO Capital Partners LLP (“GHO”), a specialist investor in global healthcare, today announced the completion of the sale of Biocare Medical ("Biocare"), a global leader in immunohistochemistry (IHC), in situ hybridization (ISH) and fluorescence in situ hybridization (FISH) solutions, to Agilent Technologies, Inc. ("Agilent", NYSE:A).
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the successful completion of its previously announced acquisition of Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP. Following the close of the transaction, Biocare is now part of Agilent's Life Sciences and Diagnostics Markets Group.“We are pleased to complete our acquisition of Biocare, which represents a natural and st.
Key metrics vs top competitors for Agilent Technologies, Inc. (A)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $131.14 | $37.04B | 28.70 | 6.73% | 18.75% | 20.62% | 0.76% | |
| $374.93 | $24.44B | 34.84 | 6.99% | 11.91% | 8.04% | — | |
| $516.62 | $191.99B | 29.12 | 3.91% | 15.18% | 13.23% | — | |
| $194.19 | $137.44B | 38.53 | 2.9% | 14.89% | 7.06% | — | |
| $58.25 | $8.87B | -388.33 | 2.08% | -0.34% | -0.5% | — | |
| $1295.59 | $26.18B | 30.72 | 3.98% | 21.4% | — | — |
Agilent Technologies, Inc. (A) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Agilent Technologies, Inc. (A) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 27, 2026·SEC
May 4, 2026·SEC
Apr 3, 2026·SEC
Get notified when A posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Agilent Technologies, Inc. (A) stock FAQ — growth, dividends, profitability & financials explained
Agilent Technologies, Inc. (A) reported $7.23B in revenue for fiscal year 2025. This represents a 9% decrease from $7.95B in 1998.
Agilent Technologies, Inc. (A) grew revenue by 6.7% over the past year. This is steady growth.
Yes, Agilent Technologies, Inc. (A) is profitable, generating $1.41B in net income for fiscal year 2025 (18.8% net margin).
Yes, Agilent Technologies, Inc. (A) pays a dividend with a yield of 0.76%. This makes it attractive for income-focused investors.
Agilent Technologies, Inc. (A) has a return on equity (ROE) of 20.6%. This is excellent, indicating efficient use of shareholder capital.
Agilent Technologies, Inc. (A) generated $1.26B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
